TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Behavioral Activation (BA) for Medication-responsive Chronically Depressed Patients With Impaired Social Functioning
Brief Summary: The investigators aimed to assess the ability of a modified version of Behavioral Activation for occupational and social improvement to produce change in: 1. social adjustment, 2. work functioning, 3. avoidance behavior and 4. behavioral activation.


Options:
A: Arm Label: Mindfulness-based Cognitive Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness-based Cognitive Therapy, Biological: Standard psychiatric care | Arm Label: CBASP; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: The Cognitive Behavioral Analysis System of Psychotherapy, Biological: Standard psychiatric care | Arm Label: Treatment-as-usual; Type: ACTIVE_COMPARATOR; Interventions: Biological: Standard psychiatric care | Intervention Type: BEHAVIORAL; Name: Mindfulness-based Cognitive Therapy; Assigned to Arm(s): Mindfulness-based Cognitive Therapy | Intervention Type: BEHAVIORAL; Name: The Cognitive Behavioral Analysis System of Psychotherapy; Assigned to Arm(s): CBASP | Intervention Type: BIOLOGICAL; Name: Standard psychiatric care; Assigned to Arm(s): CBASP, Mindfulness-based Cognitive Therapy, Treatment-as-usual
B: Arm Label: Mindfulness Based Cognitive Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness Based Cognitive Therapy | Arm Label: Combination; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness Based Cognitive Therapy, Drug: Optimal Medical Care | Arm Label: Optimal Medical Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Optimal Medical Care | Intervention Type: BEHAVIORAL; Name: Mindfulness Based Cognitive Therapy; Assigned to Arm(s): Combination, Mindfulness Based Cognitive Therapy | Intervention Type: DRUG; Name: Optimal Medical Care; Assigned to Arm(s): Combination, Optimal Medical Care
C: Arm Label: Behavioral Activation for Return to Work; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Activation for return to work | Intervention Type: BEHAVIORAL; Name: Behavioral Activation for return to work; Assigned to Arm(s): Behavioral Activation for Return to Work
D: Arm Label: CBASP; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Analysis System of Psychotherapy | Arm Label: SYSP; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: System of Supportive Psychotherapy | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Analysis System of Psychotherapy; Assigned to Arm(s): CBASP | Intervention Type: BEHAVIORAL; Name: System of Supportive Psychotherapy; Assigned to Arm(s): SYSP

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Three-arm, Randomized, Open Label, Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in the Treatment of Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Prior Letrozole or Anastrozole.
Brief Summary: This was a three-arm, randomized, open label, multi-center phase II study investigating the combination of everolimus (10mg daily) with exemestane (25mg daily) versus everolimus (10mg daily) versus capecitabine (1250mg/m2 twice daily for 14 days, 3-week cycle) in patients with estrogen-receptor positive, HER2 negative, advanced breast cancer after recurrence or progression on letrozole or anastrozole.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: E7389 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Physician's Choice | Intervention Type: DRUG; Name: E7389; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Physician's Choice; Assigned to Arm(s): 2
B: Arm Label: Capecitabine 1250 mg/m2; Type: EXPERIMENTAL; Interventions: Drug: Capecitabine | Arm Label: Everolimus 10 mg; Type: EXPERIMENTAL; Interventions: Drug: Everolimus | Arm Label: Everolimus 10 mg + Exemestane 25 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Exemestane, Drug: Everolimus | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Capecitabine 1250 mg/m2 | Intervention Type: DRUG; Name: Exemestane; Assigned to Arm(s): Everolimus 10 mg + Exemestane 25 mg | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus 10 mg, Everolimus 10 mg + Exemestane 25 mg
C: Arm Label: Arm A: bevacizumab and paclitaxel; Type: ACTIVE_COMPARATOR; Interventions: Biological: bevacizumab, Paclitaxel | Arm Label: Arm B: bevacizumab, cyclophosphamide and capecitabine; Type: ACTIVE_COMPARATOR; Interventions: Biological: Bevacizumab, Cyclophosphamide, Capecitabine | Intervention Type: BIOLOGICAL; Name: bevacizumab, Paclitaxel; Assigned to Arm(s): Arm A: bevacizumab and paclitaxel | Intervention Type: BIOLOGICAL; Name: Bevacizumab, Cyclophosphamide, Capecitabine; Assigned to Arm(s): Arm B: bevacizumab, cyclophosphamide and capecitabine
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Eribulin Mesylate | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine | Intervention Type: DRUG; Name: Eribulin Mesylate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: e-Learning & Development of an Evidence-based Psychoeducational Programme for First Episode Psychosis
Brief Summary: Treatment delay in psychosis usually lead to slower recovery, an increase in associated comorbidity and greater deterioration in social and family life of patients. Previous studies indicate that an early intervention with guidelines for increasing adherence to treatment, disease awareness and condition management leads to better progression of the disorder and is therefore related to a better prognosis.

Several studies have found that the rate of relapse is higher in patients with pharmacological treatment alone compared to those also receiving psychoeducation, who tend to improve their adherence to treatment and reduce toxic drugs dosage.

Hypotheses:

* Individual psychoeducation will be effective as complementary therapy to pharmacological treatment in patients with a first psychotic episode, improving disease evolution.
* BDNF levels will increase more in the patients receiving individual therapy compared to those without it.
* Psychoeducation can be performed similarly in all participating centers if the therapists receive the same training and use the same psychoeducation material.
* The use of telemedicine for the follow-up of the patients will help improve the welfare work and therefore the disease evolution.


Options:
A: Intervention Type: BEHAVIORAL; Name: Integrated treatment, family involvement; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Social skills training; Assigned to Arm(s): N/A
B: Arm Label: Individual psychoeducation; Type: EXPERIMENTAL; Interventions: Other: Individual psychoeducation | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Control | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control | Intervention Type: OTHER; Name: Individual psychoeducation; Assigned to Arm(s): Individual psychoeducation
C: Arm Label: Treatment As Usual (TAU); Type: ACTIVE_COMPARATOR; Interventions: Other: Treatment As Usual (TAU) | Arm Label: TAU+CBT for pts+Family Intervention+CM; Type: EXPERIMENTAL; Interventions: Behavioral: TAU+CBT for pts+Family Intervention+CM. | Intervention Type: OTHER; Name: Treatment As Usual (TAU); Assigned to Arm(s): Treatment As Usual (TAU) | Intervention Type: BEHAVIORAL; Name: TAU+CBT for pts+Family Intervention+CM.; Assigned to Arm(s): TAU+CBT for pts+Family Intervention+CM
D: Intervention Type: BEHAVIORAL; Name: integrated psychosocial treatment (behavior); Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Efficacy and Safety Study of Electro-acupuncture for Simple Female Stress Urinary Incontinence- a Multicenter, Randomized Controlled Trial
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of electroacupuncture （EA） for simple female stress urinary incontinence.


Options:
A: Arm Label: electroacupuncture group; Type: EXPERIMENTAL; Interventions: Device: electroacupuncture group | Arm Label: sham electroacupuncture group; Type: EXPERIMENTAL; Interventions: Device: sham electroacupuncture group | Intervention Type: DEVICE; Name: electroacupuncture group; Assigned to Arm(s): electroacupuncture group | Intervention Type: DEVICE; Name: sham electroacupuncture group; Assigned to Arm(s): sham electroacupuncture group
B: Arm Label: Electroacupuncture group; Type: EXPERIMENTAL; Interventions: Device: Electroacupuncture | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Device: Sham Electroacupuncture | Arm Label: Solifenacin Succinate group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Solifenacin Succinate | Intervention Type: DEVICE; Name: Electroacupuncture; Assigned to Arm(s): Electroacupuncture group | Intervention Type: DEVICE; Name: Sham Electroacupuncture; Assigned to Arm(s): Placebo group | Intervention Type: DRUG; Name: Solifenacin Succinate; Assigned to Arm(s): Solifenacin Succinate group
C: Arm Label: EA; Type: EXPERIMENTAL; Interventions: Other: electroacupncture | Arm Label: Medication; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mirabegron 50 MG [Myrbetriq] | Intervention Type: OTHER; Name: electroacupncture; Assigned to Arm(s): EA | Intervention Type: DRUG; Name: Mirabegron 50 MG [Myrbetriq]; Assigned to Arm(s): Medication
D: Arm Label: EA group; Type: ACTIVE_COMPARATOR; Interventions: Other: EA | Arm Label: Sham EA group; Type: PLACEBO_COMPARATOR; Interventions: Other: sham EA | Intervention Type: OTHER; Name: EA; Assigned to Arm(s): EA group | Intervention Type: OTHER; Name: sham EA; Assigned to Arm(s): Sham EA group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Short Term Effects of Ivacaftor in Non-G551D Cystic Fibrosis Patients
Brief Summary: This is a study of the short-term effects of ivacaftor on sweat chloride concentration and lung function in cystic fibrosis (CF) patients who fall outside current FDA approval. This new, first of its kind drug is approved for use only in CF patients with the G551D mutation in whom it safely confers considerable benefits. However, it is highly likely that CF patients with many other mutations can benefit similarly from this drug, some of whom can be identified by phenotype or genotype.

We will enroll up to 30 CF subjects with clinical presentations in which there is one or more signs of residual CF channel function. The signs of residual function include: normal digestion, concentration of chloride in sweat between 55 and 85, or milder than expected CF disease in a CF patient with severe gene mutations. The primary outcome measure will be the difference in sweat chloride concentration measured in subjects on placebo and on ivacaftor. Secondary outcome measured will be lung function.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 150 mg Ivacaftor q12h; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): 150 mg Ivacaftor q12h | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: ivacaftor-placebo; Type: EXPERIMENTAL; Interventions: Drug: ivacaftor, Drug: Placebo | Arm Label: placebo-ivacaftor; Type: EXPERIMENTAL; Interventions: Drug: ivacaftor, Drug: Placebo | Intervention Type: DRUG; Name: ivacaftor; Assigned to Arm(s): ivacaftor-placebo, placebo-ivacaftor | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): ivacaftor-placebo, placebo-ivacaftor
C: Arm Label: Riociguat (Adempas, BAY63-2521); Type: EXPERIMENTAL; Interventions: Drug: Riociguat (Adempas, BAY63-2521) | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Riociguat (Adempas, BAY63-2521); Assigned to Arm(s): Riociguat (Adempas, BAY63-2521) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Ataluren; Type: EXPERIMENTAL; Interventions: Drug: Ataluren | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ataluren; Assigned to Arm(s): Ataluren | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multimedia HIV/STI Prevention for Drug-Involved Female Offenders
Brief Summary: The proposed study addresses a significant public health threat of Human immunodeficiency virus (HIV) and sexually transmitted infections (STIs) among drug involved women on probation, parole or other community supervision. This randomized controlled trial aims to test the efficacy of a multimedia version of a 4-session, gender-specific, integrated drug use and HIV/STI prevention intervention (Multimedia Women On the Road To Health (WORTH)) in increasing condom use and decreasing the incidence of sexually transmitted infections (STIs) among 420 drug-involved, female offenders in a large community court setting in New York City, compared to a non-media version of the same intervention (Traditional WORTH) and to a 4-session Wellness Promotion condition.


Options:
A: Arm Label: Strength at Home Couples Group; Type: EXPERIMENTAL; Interventions: Behavioral: Strength at Home Couples Group | Arm Label: Supportive Group Therapy; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Supportive Group Therapy | Intervention Type: BEHAVIORAL; Name: Strength at Home Couples Group; Assigned to Arm(s): Strength at Home Couples Group | Intervention Type: BEHAVIORAL; Name: Supportive Group Therapy; Assigned to Arm(s): Supportive Group Therapy
B: Arm Label: Brief Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Enhancement Therapy | Arm Label: Assessed Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: No Contact Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Motivational Enhancement Therapy; Assigned to Arm(s): Brief Intervention Group
C: Arm Label: Motivational Interviewing (MI); Type: EXPERIMENTAL; Interventions: Behavioral: Motivational interviewing (MI) | Intervention Type: BEHAVIORAL; Name: Motivational interviewing (MI); Assigned to Arm(s): Motivational Interviewing (MI)
D: Arm Label: Multimedia HIV/STI prevention; Type: EXPERIMENTAL; Interventions: Behavioral: Multimedia WORTH | Arm Label: Traditional HIV/STI prevention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Traditional WORTH | Arm Label: Wellness Promotion; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Wellness Promotion | Intervention Type: BEHAVIORAL; Name: Multimedia WORTH; Assigned to Arm(s): Multimedia HIV/STI prevention | Intervention Type: BEHAVIORAL; Name: Traditional WORTH; Assigned to Arm(s): Traditional HIV/STI prevention | Intervention Type: BEHAVIORAL; Name: Wellness Promotion; Assigned to Arm(s): Wellness Promotion

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3 Randomized Controlled Trial Evaluating the Effect of Laparoscopic Roux-en-Y Gastric Bypass (LRYGB) on Hypertension Medication Reduction, Blood Pressure Levels and Others Cardiovascular Risk Factors.
Brief Summary: Phase 3, unicentric, randomized clinical trial, with allocation concealment and intention-to-treat analysis to evaluate the efficacy of videolaparoscopic Roux-en-Y Gastroplasty to decrease the prescription of antihypertensive drugs maintaining normal levels of blood pressure, decrease systemic arterial blood pressure and other risk factors for cardiovascular events compared to clinical treatments of patients with arterial hypertension.


Options:
A: Arm Label: Treatment group; Type: ACTIVE_COMPARATOR; Interventions: Device: placement of g-Cath EZ suture anchors, Behavioral: Diet and Exercise | Arm Label: Sham Group; Type: SHAM_COMPARATOR; Interventions: Procedure: Sham procedure, Behavioral: Diet and Exercise | Intervention Type: DEVICE; Name: placement of g-Cath EZ suture anchors; Assigned to Arm(s): Treatment group | Intervention Type: PROCEDURE; Name: Sham procedure; Assigned to Arm(s): Sham Group | Intervention Type: BEHAVIORAL; Name: Diet and Exercise; Assigned to Arm(s): Sham Group, Treatment group
B: N/A
C: Arm Label: Laparoscopic Roux-en-Y gastric bypass; Type: EXPERIMENTAL; Interventions: Procedure: Laparoscopic Roux-en-Y gastric bypass (LRYGB), Other: Clinical treatment | Arm Label: Clinical treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: Clinical treatment | Intervention Type: PROCEDURE; Name: Laparoscopic Roux-en-Y gastric bypass (LRYGB); Assigned to Arm(s): Laparoscopic Roux-en-Y gastric bypass | Intervention Type: OTHER; Name: Clinical treatment; Assigned to Arm(s): Clinical treatment, Laparoscopic Roux-en-Y gastric bypass
D: Arm Label: Laparoscopic adjustable gastric band; Type: EXPERIMENTAL; Interventions: Procedure: laparoscopic adjustable gastric band, Behavioral: Combined life style interventions | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Combined life style interventions | Intervention Type: PROCEDURE; Name: laparoscopic adjustable gastric band; Assigned to Arm(s): Laparoscopic adjustable gastric band | Intervention Type: BEHAVIORAL; Name: Combined life style interventions; Assigned to Arm(s): Control group, Laparoscopic adjustable gastric band

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized ph. II Study to Explore Efficacy and Feasibility of Upfront Rotations Between SUNitinib and Everolimus vs Sequential Treatment of 1st lIne Sunitinib & 2nd Line EverolimuS Until Progression in Pats Met. Clear Cell Renal Cancer
Brief Summary: The objective of this study is to assess the progression-free survival, of patients who receive rotations of sunitinib and everolimus versus patients who receive sunitinib as a first line treatment followed by everolimus when progression occurs.


Options:
A: Arm Label: Bevacizumab + IFN-Alfa-2A; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab [Avastin], Drug: Interferon alfa 2a [Roferon] | Arm Label: Placebo + IFN-Alfa-2A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Interferon alfa 2a [Roferon], Drug: Placebo | Intervention Type: DRUG; Name: Bevacizumab [Avastin]; Assigned to Arm(s): Bevacizumab + IFN-Alfa-2A | Intervention Type: DRUG; Name: Interferon alfa 2a [Roferon]; Assigned to Arm(s): Bevacizumab + IFN-Alfa-2A, Placebo + IFN-Alfa-2A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + IFN-Alfa-2A
B: Arm Label: LY2510924 + Sunitinib; Type: EXPERIMENTAL; Interventions: Drug: LY2510924, Drug: Sunitinib | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: LY2510924; Assigned to Arm(s): LY2510924 + Sunitinib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): LY2510924 + Sunitinib, Sunitinib
C: Arm Label: Rotational arm; Type: EXPERIMENTAL; Interventions: Drug: Sunitinib, Drug: Everolimus | Arm Label: Sequential arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib, Drug: Everolimus | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Rotational arm, Sequential arm | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Rotational arm, Sequential arm
D: Arm Label: Arm A: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm B: Sunitinib 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Biological: Nivolumab, Biological: Ipilimumab, Drug: Sunitinib | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg, Arm B: Sunitinib 50 mg | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Arm A: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg, Arm B: Sunitinib 50 mg | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Arm B: Sunitinib 50 mg

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prophylactic Haloperidol Use for Delirium in ICU Patients; a Randomized Placebo-controlled Double-blind Multicentre Trial
Brief Summary: The aim of this study is to determine the effects of a low dosage of prophylactic haloperidol in patients with a high risk to develop delirium, defined by an expected ICU length of stay of \>1 day. The investigators hypothesized that haloperidol prophylaxis in patients with a high risk for delirium reduces 28-day mortality, delirium and delirium related outcome.

Two different dosages of haloperidol are used in this study to compare with placebo. A dosage of 1mg, or 2mg or placebo three times a day in a double-blinded fashion resulting in a three-armed multicentre randomized double-blinded placebo-controlled trial. To relate the potential beneficial effects of haloperidol to the a priori risk to develop delirium, the PREDELIRIC-model (delirium prediction model for ICU patients) will be used. This will enable the investigators to determine the preventive efficacy of haloperidol in patient groups based on their risk to develop delirium.


Options:
A: Arm Label: PS; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Protocolized Sedation | Arm Label: PS + DI; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Protocolized sedation, with daily interruption | Intervention Type: PROCEDURE; Name: Protocolized Sedation; Assigned to Arm(s): PS | Intervention Type: PROCEDURE; Name: Protocolized sedation, with daily interruption; Assigned to Arm(s): PS + DI
B: Arm Label: Haloperidol 1mg/q8h; Type: EXPERIMENTAL; Interventions: Drug: Haloperidol 1 mg/q8h | Arm Label: Haloperidol 2mg/q8h; Type: EXPERIMENTAL; Interventions: Drug: Haloperidol 2 mg/q8h | Arm Label: Sodium chloride 0.9%; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Haloperidol 1 mg/q8h; Assigned to Arm(s): Haloperidol 1mg/q8h | Intervention Type: DRUG; Name: Haloperidol 2 mg/q8h; Assigned to Arm(s): Haloperidol 2mg/q8h | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sodium chloride 0.9%
C: Arm Label: dexmedetomidine group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexmedetomidine | Arm Label: propofol group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): dexmedetomidine group
D: Arm Label: Early PT OT; Type: EXPERIMENTAL; Interventions: Procedure: early PT OT | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: early PT OT; Assigned to Arm(s): Early PT OT

Answer: B